Send to

Choose Destination
Asian J Transfus Sci. 2019 Jul-Dec;13(2):120-128. doi: 10.4103/ajts.AJTS_44_18. Epub 2019 Dec 3.

Effectiveness of bone marrow-derived mononuclear stem cells for neurological recovery in participants with spinal cord injury: A randomized controlled trial.

Author information

Department of Orthopedic Surgery, King George's Medical University, Lucknow, Uttar Pradesh, India.
Department of Transfusion Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India.



Complete lesion after spinal cord injury (SCI) remains irreversible with little hope of neurological recovery. Newer interventions such as re-stimulation of damaged neurons using artificial agents and the use of stem cells for neuronal regeneration have shown promising results.


This study was undertaken for evaluating the neurological status of acute SCI participants after stem cell augmentation and comparing them with other treatment methods.


Randomized controlled trial in the northern Indian population.


A total 193 SCI participants of complete paraplegia with unstable T4-L2 injury having thoracolumbar injury severity score ≥4 were enrolled in this study. Participants were randomly allocated for three different treatment modalities, namely, conventional with stem cell augmentation (Group-1), conventional (Group-2), and conservative (Group-3). Neurological recovery after 1 year was evaluated through the ASIA Impairment Scale (AIS)-grading, sensory, and motor scores.


T-test for sensory-motor score analysis of each group and analysis of variance for comparison of same variables between the groups.


After 1-year significant difference was observed in the AIS-grade, sensory and motor scores in-Group 1 (P < 0.001). In Group-1 versus 2, the mean difference at 1 year for AIS grade, sensory and motor scores were 0.40 (P = 0.010, 95% confidence interval [CI] 0.075-0.727), 8.52 (P = 0.030, 95% CI 0.619-16.419), and 4.55(P = 0.003, 95% CI 1.282-7.815), respectively. In Group-1 versus 3, 1.03, 19.02 and 7.22 (P < 0.001 for each of the parameters) and in Group-2 versus 3, 0.63 (P < 0.001), 10.49 (P = 0.009), and 2.68 (P = 0.019), respectively.


Significant motor neurological recovery and AIS-grade promotion was observed in Group-1 as compared to Group-2 and 3.


Acute spinal cord injury; autologous bone marrow mononuclear stem cells; conventional treatment; neurological recovery; thoracolumbar injury severity score

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center